EP0831803A1 - Sorbic-acid-containing hydrogels - Google Patents

Sorbic-acid-containing hydrogels

Info

Publication number
EP0831803A1
EP0831803A1 EP96917458A EP96917458A EP0831803A1 EP 0831803 A1 EP0831803 A1 EP 0831803A1 EP 96917458 A EP96917458 A EP 96917458A EP 96917458 A EP96917458 A EP 96917458A EP 0831803 A1 EP0831803 A1 EP 0831803A1
Authority
EP
European Patent Office
Prior art keywords
sorbic acid
hydrogel
pharmaceutical preparations
weight
acid
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Withdrawn
Application number
EP96917458A
Other languages
German (de)
French (fr)
Inventor
Karin Hoffmann
Jutta Riedl
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Bayer Pharma AG
Original Assignee
Schering AG
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Schering AG filed Critical Schering AG
Publication of EP0831803A1 publication Critical patent/EP0831803A1/en
Withdrawn legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A61K31/19—Carboxylic acids, e.g. valproic acid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
    • A61K47/32—Macromolecular compounds obtained by reactions only involving carbon-to-carbon unsaturated bonds, e.g. carbomers, poly(meth)acrylates, or polyvinyl pyrrolidone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0014—Skin, i.e. galenical aspects of topical compositions

Definitions

  • the invention relates to pharmaceutical preparations in the form of a hydrogel, which are characterized in that they contain sorbic acid, if appropriate in combination with a polyhydric alcohol and / or a polyhydric ether, as the sole active ingredients.
  • these preparation forms can contain polyhydric alcohols and / or polyhydric ethers, such as, for example, ethylene glycol, propylene glycol, glycerol or a polyoxyalkylene, which serve to prevent the skin from drying out and to keep it supple (humefectant, emolliant and softening agents) (Ullmann's Encyclopedia of Industrial Chemistry, 5th Ed., VCH-Verlagsgesellschaft mbH, D-69451 Weinheim (DE), 1993, Volume AlO, p lOlff, Volume A21, p 579ff and Volume A22, p 163)
  • these additives can also serve as agents for enhancing the penetration of the active ingredients (enhancers).
  • Suitable polyvalent alcohols and / or polyvalent ethers for the pharmaceutical preparations according to the invention are preferably physiologically harmless, liquid substances of these classes of substances, as are usually used in such preparations.
  • Such compounds are, for example, those of the general formula II
  • n is a number from 1 to 12 (preferably 1 to 8) and
  • R is a hydrogen atom, a methyl group or, if n is 1, also a
  • Suitable alcohols or ethers of the general formula I are, for example, ethylene glycol, propylene glycol, glycerol, diethylene glycol, triethylene glycol, dipropylene glycol or tripropylene glycol. These are substances which are also used in pharmaceutical preparations intended for topical application as enhancers for the active ingredients used in the preparations (see, for example, EP-A 0 165 696, WO 88/01496 and DE-A 2 515 594).
  • the pharmaceutical preparations according to the invention can also contain, for example, cyclic polyols or polyethers such as dimethyl isosorbide or glycol ethers such as diglycol dimethyl ether as polyhydric alcohols or polyhydric ethers.
  • cyclic polyols or polyethers such as dimethyl isosorbide or glycol ethers such as diglycol dimethyl ether as polyhydric alcohols or polyhydric ethers.
  • glycol ethers such as diglycol dimethyl ether as polyhydric alcohols or polyhydric ethers.
  • propylene glycol has proven to be particularly suitable.
  • the pharmaceutical preparations according to the invention in the form of a hydrogel can contain, for example, 0.05 to 2.5% by weight and preferably 0.1 to 1.0% by weight of sorbic acid and 0 to 30% by weight and preferably 5 to 20% by weight of a polyvalent Contain alcohol and / or a polyvalent ether.
  • Suitable thickeners are, for example, gel-forming polysaccharides and proteins such as gelatin, agar-agar, pectins, and dextrins or in particular polyacrylates, such as those of the Carbopol® type (Goodrich Chem., Cleveland, USA).
  • a suitable preparation in the form of a hydrogel can have, for example, the following composition:
  • Carbopol® 980 0.5 2.0%
  • sorbic acid 12.0 g of propylene glycol and 76.55 g of purified water are mixed, heated to 35 ° C. and the sorbic acid is dissolved with stirring. The solution is then cooled to 20 ° C., 1.0 g of Carbopol® are added and the mixture is homogenized. A solution of 10.0 g of sodium hydroxide in 10.25 g of purified water is then added to the mixture and the mixture is homogenized until the gel structure has completely formed.
  • the developed hydrogel base with sorbic acid also shows a strong antimicrobial activity and a clear influence on the inflammation process in acne, which goes far beyond the expected vehicle effect of a preserved hydrogel base.

Abstract

The description relates to pharmaceutical preparations in the form of a hydrogel which contain sorbic acid, possibly in combination with a polyvalent alcohol and/or a polyvalent ether, as the sole active agent.

Description

Sorbinsäure haltige Hydrogele Hydrogels containing sorbic acid
Die Erfindung betrifft pharmazeutische Präparate in Form eines Hydrogels, welche dadurch gekennzeichnet sind, daß sie Sorbinsäure gegebenenfalls in Kombination mit einem mehrwertigen Alkohol und/oder einem mehrwertigen Ether als alleinige Wirkstoffe enthalten.The invention relates to pharmaceutical preparations in the form of a hydrogel, which are characterized in that they contain sorbic acid, if appropriate in combination with a polyhydric alcohol and / or a polyhydric ether, as the sole active ingredients.
Es ist bekannt, daß pharmazeutische Präparate in Form eines Hydrogels, die zur topischen Applikation bestimmt sind, wie zum Beispiel Salben oder Cremes, Sorbinsäure (2,4-Hexadiensäure) der Formel IIt is known that pharmaceutical preparations in the form of a hydrogel, which are intended for topical application, such as ointments or creams, sorbic acid (2,4-hexadienoic acid) of the formula I
CH -CH=CH-CH=CH-COOH (I),CH-CH = CH-CH = CH-COOH (I),
enthalten können, welche zur Konservierung der Zubereitungen dient (Ullmann's Encyclopedia of Industrial Chemistry, 5th Ed. VCH Verlagsgesellschaft mbH D-69451 Weinheim (DE), 1993, Band A24, p507ff).May contain, which serves to preserve the preparations (Ullmann's Encyclopedia of Industrial Chemistry, 5th Ed.VCH Verlagsgesellschaft mbH D-69451 Weinheim (DE), 1993, Volume A24, p507ff).
Femer ist bekannt, daß diese Zubereitungsformen mehrwertige Alkohole und/oder mehrwertige Ether, wie zum Beispiel Ethylenglycol, Propylenglycol, Glycerol oder ein Polyoxyalkylen enthalten können, die dazu dienen, die Haut vor dem Austrocknen zu bewahren und geschmeidig zu erhalten (humefectant, emolliant und softening agents) (Ullmann 's Encyclopedia of Industrial Chemistry, 5th Ed., VCH- Verlagsgesellschaft mbH, D-69451 Weinheim (DE), 1993, Band AlO, p lOlff, Band A21, p 579ff und Band A22, p 163) Im Falle wirkstoffhaltiger Zubereitungen können diese Zusätze gegebenenfalls auch als Mittel zur Penetrationsverstärkung der Wirkstoffe (enhancer) dienen.It is also known that these preparation forms can contain polyhydric alcohols and / or polyhydric ethers, such as, for example, ethylene glycol, propylene glycol, glycerol or a polyoxyalkylene, which serve to prevent the skin from drying out and to keep it supple (humefectant, emolliant and softening agents) (Ullmann's Encyclopedia of Industrial Chemistry, 5th Ed., VCH-Verlagsgesellschaft mbH, D-69451 Weinheim (DE), 1993, Volume AlO, p lOlff, Volume A21, p 579ff and Volume A22, p 163) In the case In the case of preparations containing active ingredients, these additives can also serve as agents for enhancing the penetration of the active ingredients (enhancers).
Es wurde nun gefunden, daß pharmazeutische Präparate in Form eines Hydrogels, die Sorbinsäure vorzugsweise in Kombination mit einem mehrwertigen Alkohol und/oder einem mehrwertigen Ether als alleinige Wirkstoffe enthalten, überraschenderweise bei topischer Applikation eine stark ausgeprägt heilende Wirkung auf entzündliche Effloreszenzen bei Aknepatienten zeigen, wie in dem nachfolgenden Ausführungsbeispiel näher erläutert wird. Für die erfindungsgemäßen pharmazeutischen Präparate eignen sich als mehrwertige Alkohole und/oder mehrwertige Ether vorzugsweise physiologisch unbedenkliche, flüssige Substanzen dieser Stoffklassen, wie sie üblicherweise in derartigen Zubereitungen verwendet werden. Solche Verbindungen sind beispielweise solche der allgemeinen Formel IIIt has now been found that pharmaceutical preparations in the form of a hydrogel, which contain sorbic acid preferably in combination with a polyhydric alcohol and / or a polyhydric ether as the sole active ingredients, surprisingly show a highly pronounced healing effect on inflammatory efflorescences in acne patients when applied topically, as is the case is explained in more detail in the following embodiment. Suitable polyvalent alcohols and / or polyvalent ethers for the pharmaceutical preparations according to the invention are preferably physiologically harmless, liquid substances of these classes of substances, as are usually used in such preparations. Such compounds are, for example, those of the general formula II
H-(0-CHR-CH2)n-OH (II),H- (0-CHR-CH2) n-OH (II),
worin n eine Ziffer von 1 bis 12 (vorzugweise 1 bis 8) bedeutet undwhere n is a number from 1 to 12 (preferably 1 to 8) and
R ein Wasserstoffatom, eine Methylgruppe oder, falls n die Ziffer 1 ist auch eineR is a hydrogen atom, a methyl group or, if n is 1, also a
Hydroxymethylgruppe darstellt.Represents hydroxymethyl group.
Geeignete Alkohole oder Ether der allgemeinen Formel I sind beispielsweise das Ethylenglycol, das Propylenglycol, das Glycerol, das Diethylenglycol, das Triethylen- glycol, das Dipropylenglycol oder das Tripropylenglycol. Dies sind Substanzen, die in zur topischen Applikation bestimmten pharmazeutischen Präparaten auch als enhancer für die in den Präparaten verwendeten Wirkstoffe Verwendung finden (siehe beispielsweise die EP-A 0 165 696, die WO 88/01496 und die DE-A 2 515 594).Suitable alcohols or ethers of the general formula I are, for example, ethylene glycol, propylene glycol, glycerol, diethylene glycol, triethylene glycol, dipropylene glycol or tripropylene glycol. These are substances which are also used in pharmaceutical preparations intended for topical application as enhancers for the active ingredients used in the preparations (see, for example, EP-A 0 165 696, WO 88/01496 and DE-A 2 515 594).
Andererseits können die erfindungsgemäßen pharmazeutischen Präparate als mehrwertige Alkohole oder mehrwertige Ether beispielsweise auch cyclische Polyole oder Polyether wie etwa das Dimethylisosorbid oder Glycolether wie den Diglycoldimethylether enthalten. Bei den bislang durchgeführten Untersuchungen hat sich das Propylenglycol als besonders geeignet erwiesen.On the other hand, the pharmaceutical preparations according to the invention can also contain, for example, cyclic polyols or polyethers such as dimethyl isosorbide or glycol ethers such as diglycol dimethyl ether as polyhydric alcohols or polyhydric ethers. In the studies carried out so far, propylene glycol has proven to be particularly suitable.
Die erfindungsgemäßen pharmazeutischen Präparate in Form eines Hydrogels können beispielsweise 0,05 bis 2,5 Gew. % und vorzugsweise 0,1 bis 1,0 Gew. % Sorbinsäure sowie 0 bis 30 Gew. % und vorzugsweise 5 bis 20 Gew. % eines mehrwertigen Alkohols und/oder eines mehrwertigen Ethers enthalten.The pharmaceutical preparations according to the invention in the form of a hydrogel can contain, for example, 0.05 to 2.5% by weight and preferably 0.1 to 1.0% by weight of sorbic acid and 0 to 30% by weight and preferably 5 to 20% by weight of a polyvalent Contain alcohol and / or a polyvalent ether.
Zur Bildung der Hydrogele können die üblichen Verdickungsmittel verwendet werden (Ullmann 's Encyclopedia of Industrial Chemistry, 5th Ed., Vol. A24, Seite 220 ff.). Geeignete Verdickungsmittel sind beispielsweise gelbildende Polysaccharide und Proteine wie Gelatine, Agar-Agar, Pectine, und Dextrine oder insbesondere Polyacrylate, wie solche des Carbopol®-Typs (Goodrich Chem., Cleveland, U.S.A.). Ein geeignetes Präparat in Form eines Hydrogels kann erfindungsgemäß beispielsweise folgende Zusammensetzung haben:The usual thickeners can be used to form the hydrogels (Ullmann's Encyclopedia of Industrial Chemistry, 5th Ed., Vol. A24, page 220 ff.). Suitable thickeners are, for example, gel-forming polysaccharides and proteins such as gelatin, agar-agar, pectins, and dextrins or in particular polyacrylates, such as those of the Carbopol® type (Goodrich Chem., Cleveland, USA). According to the invention, a suitable preparation in the form of a hydrogel can have, for example, the following composition:
Sorbinsäure 0,15 0,50%Sorbic acid 0.15 0.50%
Propylenglycol 10,0 15,0%Propylene glycol 10.0 15.0%
Carbopol® 980 0,5 2,0%Carbopol® 980 0.5 2.0%
Natriumhydroxid 0,2 0,5% gereinigtes Wasser ad 100%Sodium hydroxide 0.2 0.5% purified water ad 100%
(Angaben in Gewichtsprozent).(Figures in percent by weight).
Das nachfolgende Ausführungsbeispiel dient zur näheren Erläuterung der Erfindung: The following exemplary embodiment serves to explain the invention in more detail:
Beispielexample
0,2 g Sorbinsäure, 12,0 g Propylenglycol und 76,55 g gereinigtes Wasser werden gemischt, auf 35 °C erwärmt und die Sorbinsäure unter Rühren gelöst. Danach kühlt man die Lösung auf 20°C ab, versetzt mit 1,0 g Carbopol® und homogenisiert. Dann setzt man dem Gemisch eine Lösung von 10.0 g Natriumhydroxid in 10.25 g gereinigtem Wasser zu und homogenisiert die Mischung bis zur vollständigen Ausbildung des Gelgerüstes.0.2 g of sorbic acid, 12.0 g of propylene glycol and 76.55 g of purified water are mixed, heated to 35 ° C. and the sorbic acid is dissolved with stirring. The solution is then cooled to 20 ° C., 1.0 g of Carbopol® are added and the mixture is homogenized. A solution of 10.0 g of sodium hydroxide in 10.25 g of purified water is then added to the mixture and the mixture is homogenized until the gel structure has completely formed.
Das abschließende Arzturteil aus 10 Prüfungszentren bescheinigt der getesteten Hydrogelgrundlage mit Sorbinsäure im Durchschnitt eine gute bis sehr gute Eignung für die Behandlung der mittelschweren Akne.The final doctor's judgment from 10 test centers certifies that the hydrogel base tested with sorbic acid is on average a good to very good suitability for the treatment of moderate acne.
Damit zeigt die entwickelte Hydrogelgrundlage mit Sorbinsäure auch eine starke antimikrobielle Wirksamkeit und einen deutlichen Einfluß auf das Entzündungsgeschehen bei der Akne, der weit über den zu erwartenden Vehikeleffekt einer konservierten Hydrogelgrundlage hinausgeht. The developed hydrogel base with sorbic acid also shows a strong antimicrobial activity and a clear influence on the inflammation process in acne, which goes far beyond the expected vehicle effect of a preserved hydrogel base.

Claims

Patentansprüche claims
1.) Pharmazeutische Präparate in Form eines Hydrogels, dadurch gekennzeichnet, daß sie1.) Pharmaceutical preparations in the form of a hydrogel, characterized in that they
Sorbinsäure gegebenenfalls in Kombination mit einem mehrwertigen Alkohol und/oder einem mehrwertigen Ether als alleinige Wirkstoffe enthalten.Sorbic acid optionally in combination with a polyhydric alcohol and / or a polyhydric ether as the only active ingredients.
2.) Pharmazeutische Präparate in Form eines Hydrogels gemäß Patentanspruch 1 enthaltend2.) Containing pharmaceutical preparations in the form of a hydrogel according to claim 1
Sorbinsäure 0,15 - 0,50 Gew. %Sorbic acid 0.15 - 0.50% by weight
Propylenglycol 10,0 - 15,0 Gew. %Propylene glycol 10.0 - 15.0% by weight
Carbopol® 980 0,5 - 2,0 Gew. %Carbopol® 980 0.5 - 2.0% by weight
Natriumhydroxid 0,2 - 0,5 Gew. % Sodium hydroxide 0.2-0.5% by weight
EP96917458A 1995-05-31 1996-05-30 Sorbic-acid-containing hydrogels Withdrawn EP0831803A1 (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
DE19520838 1995-05-31
DE19520838 1995-05-31
PCT/EP1996/002300 WO1996038135A1 (en) 1995-05-31 1996-05-30 Sorbic-acid-containing hydrogels

Publications (1)

Publication Number Publication Date
EP0831803A1 true EP0831803A1 (en) 1998-04-01

Family

ID=7763859

Family Applications (1)

Application Number Title Priority Date Filing Date
EP96917458A Withdrawn EP0831803A1 (en) 1995-05-31 1996-05-30 Sorbic-acid-containing hydrogels

Country Status (12)

Country Link
EP (1) EP0831803A1 (en)
JP (1) JPH11506441A (en)
KR (1) KR19990022143A (en)
CN (1) CN1185735A (en)
AU (1) AU6002796A (en)
CA (1) CA2222566A1 (en)
CZ (1) CZ374797A3 (en)
HU (1) HUP9801745A3 (en)
IS (1) IS4606A (en)
PL (1) PL323598A1 (en)
TR (1) TR199701463T1 (en)
WO (1) WO1996038135A1 (en)

Families Citing this family (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB9826656D0 (en) 1998-12-03 1999-01-27 Novartis Ag Organic compounds
BE1023757B1 (en) * 2016-06-30 2017-07-12 Yun NV STORAGE OF MICRO-ORGANISMS

Family Cites Families (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPS6333314A (en) * 1986-07-29 1988-02-13 Sansho Seiyaku Kk External preparation
US5013769A (en) * 1988-08-22 1991-05-07 Medipro Sciences Limited Method of making a hydrogel-forming wound dressing or skin coating material

Non-Patent Citations (1)

* Cited by examiner, † Cited by third party
Title
See references of WO9638135A1 *

Also Published As

Publication number Publication date
IS4606A (en) 1997-10-31
WO1996038135A1 (en) 1996-12-05
HUP9801745A3 (en) 2000-04-28
KR19990022143A (en) 1999-03-25
JPH11506441A (en) 1999-06-08
CZ374797A3 (en) 1998-04-15
PL323598A1 (en) 1998-04-14
AU6002796A (en) 1996-12-18
CA2222566A1 (en) 1996-12-05
CN1185735A (en) 1998-06-24
HUP9801745A2 (en) 1998-12-28
TR199701463T1 (en) 1998-02-21

Similar Documents

Publication Publication Date Title
EP0135617B1 (en) Gel-like ointment containing indomethacin
DE10361022A1 (en) Topical preparations containing dimethyl sulfoxide and dexpanthenol
EP0801948A1 (en) Ophthalmic composition having prolonged residence time in the eye
CH644892A5 (en) DETERGENT AND CLEANING AGENT.
CH643456A5 (en) PHARMACEUTICAL PREPARATION.
DE3027933A1 (en) PHARMACEUTICAL PREPARATION BASED ON BLUEBERRY EXTRACTS
DE69907656T2 (en) POLYETHOXYLATED RETINAMIDE DERIVATIVES AND METHOD FOR THE PRODUCTION THEREOF
EP0108318A1 (en) Buccal and dental care composition
DE2421638A1 (en) SKIN CARE AND SKIN PROTECTION PRODUCTS WITH A CONTENT OF SKIN MOISTURIZERS
EP0944579B1 (en) Aminohydrofluorides and their use as oral hygiene preparations
CH676549A5 (en)
EP0831803A1 (en) Sorbic-acid-containing hydrogels
DE2504615C3 (en) Process for the production of a gel with a content of ß-methasone-17-benzoate or fluocinolone acetonide and neomycin
EP0450123B1 (en) Pharmaceutical composition for topical administration containing diclofenac-sodium
DE2812117A1 (en) Novel bis-amine monofluorophosphates, process for their production and their use in mixtures preventing caries
DE3339196A1 (en) Antimicrobial preservative and disinfectant
DE3049038C2 (en)
DE2847975A1 (en) Free formaldehyde removal from pharmaceuticals and cosmetics - by adding urea to bind the formaldehyde
DE4304303C2 (en) Vitamin E derivatives with a quaternary nitrogen atom, process for their preparation and cosmetic compositions containing the same
DE2416556A1 (en) Skin care compsns contg. moisture-retaining agents - comprising N-hydroxyalkylated, non aromatic N-heterocyclic cpds
EP0555634A2 (en) Disinfection compositions
DE20319986U1 (en) Topical composition containing dimethyl sulfoxide (DMSO) and dexapanthenol, useful for treating e.g. injuries and rheumatic disease, can contain high concentration of DMSO without causing skin irritation
DD262530A5 (en) PROCESS FOR PREPARING A PHARMACEUTICAL WAFEREN GEL PREPARATION
DE1962969C3 (en) Light stabilizers
DE3202347A1 (en) LECITHIN HYDROGEN PEROXIDE COMPOSITION

Legal Events

Date Code Title Description
PUAI Public reference made under article 153(3) epc to a published international application that has entered the european phase

Free format text: ORIGINAL CODE: 0009012

17P Request for examination filed

Effective date: 19971001

AK Designated contracting states

Kind code of ref document: A1

Designated state(s): AT BE CH DE DK ES FI FR GB GR IE IT LI LU MC NL PT SE

STAA Information on the status of an ep patent application or granted ep patent

Free format text: STATUS: THE APPLICATION HAS BEEN WITHDRAWN

18W Application withdrawn

Withdrawal date: 19990730